Chris Martin

Chris is the Tokamak Energy Chairman and a non-executive director. He is an innovative entrepreneur with considerable international experience successfully growing businesses in the medical technology, energy and environmental sectors.

As well as leading the business and being accountable to Tokamak Energy’s shareholders and investors, Chris is also the CEO at Swiss-based ADC Therapeutics which is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematalogical cancers.

Chris is a Sainsbury Management Fellow and he holds an MBA degree from the International Institute for Management Development (IMD) in Lausanne, Switzerland. He also has a D.Phil. degree in Chemical Engineering from Oxford University.